Neuromodulation Platform Receives CE Marking for Use with 3-Tesla MRI
By MedImaging International staff writers Posted on 18 Feb 2015 |
Image: Senza SCS System Components (Photo courtesy of Nevro).
An implantable Spinal Cord Simulation (SCS) platform intended for the treatment of chronic pain has received CE marking (Conformité Européenne) approval for expanded MR-conditional (Magnetic Resonance) labeling.
The CE marking will provide patients already receiving HF10 (High-Frequency, 10 kHz) SCS treatment with access to Magnetic Resonance Imaging (MRI) scans.
All versions of the 5-year-old SCS system, produced by Nevro (Menlo Park, CA, USA), can now be marketed in Europe and Australia, and anywhere the system is sold, for use with 1.5 Tesla and 3.0 Tesla MRI scans of the head and extremities. This is the first implantable SCS system to receive 3-Tesla compatibility.
The Senza SCS system delivers electrical pulses by means of small electrodes implanted near the spinal cord and connected to a battery-powered generator also implanted under the skin.
According to Michael DeMane, Chairman and Chief Executive Officer of Nevro, “We are pleased to offer even more imaging options for our patients. Nevro is a company that is continually looking to advance the SCS space, and this expanded MR-conditional labeling highlights our ongoing commitment to innovation.”
Related Links:
Nevro
The CE marking will provide patients already receiving HF10 (High-Frequency, 10 kHz) SCS treatment with access to Magnetic Resonance Imaging (MRI) scans.
All versions of the 5-year-old SCS system, produced by Nevro (Menlo Park, CA, USA), can now be marketed in Europe and Australia, and anywhere the system is sold, for use with 1.5 Tesla and 3.0 Tesla MRI scans of the head and extremities. This is the first implantable SCS system to receive 3-Tesla compatibility.
The Senza SCS system delivers electrical pulses by means of small electrodes implanted near the spinal cord and connected to a battery-powered generator also implanted under the skin.
According to Michael DeMane, Chairman and Chief Executive Officer of Nevro, “We are pleased to offer even more imaging options for our patients. Nevro is a company that is continually looking to advance the SCS space, and this expanded MR-conditional labeling highlights our ongoing commitment to innovation.”
Related Links:
Nevro
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer